Matri Sys Bioscience
Biotechnology, 505 Coast BLVDS, La Jolla, California, 92037, United States, 1-10 Employees
Phone Number: 61********
Who is MATRISYS BIOSCIENCE
MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology...
Read More
-
Headquarters: 505 Coast BLVDS, La Jolla, California, 92037, United States
-
Date Founded: 2015
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from MATRISYS BIOSCIENCE
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding MatriSys Bioscience
Answer: MatriSys Bioscience's headquarters are located at 505 Coast BLVDS, La Jolla, California, 92037, United States
Answer: MatriSys Bioscience's phone number is 61********
Answer: MatriSys Bioscience's official website is https://matrisysbio.com
Answer: MatriSys Bioscience's revenue is $1 Million to $5 Million
Answer: MatriSys Bioscience's SIC: 2836
Answer: MatriSys Bioscience's NAICS: 541714
Answer: MatriSys Bioscience has 1-10 employees
Answer: MatriSys Bioscience is in Biotechnology
Answer: MatriSys Bioscience contact info: Phone number: 61******** Website: https://matrisysbio.com
Answer: MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology & skin care conditions - Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life. More than 230 million patients suffer from these 5 skin diseases, which represent a $12.9 Billion Rx market and a $121 Billion skin care market. MatriSys Bios scientific approach is to rebalance the natural skin microbiome by application of microbial therapies -Good Bugs that selectively target skin pathogens -Bad Bugs. Our lead microbiome Phase I/II clinical program addresses the Atopic Dermatitis (AD) market with 15 M US patients (132 M worldwide), is NIH funded, and IP protected with an exclusive license from UCSD. Our Good Bug, S. hominis, is highly potent against the Bad Bug, Staph. aureus, which has long been associated with AD. S. hominis does not affect other Good Bugs leading to the natural rebalance of the skin microbiome.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month